董事介绍
注:董事持股数取自最新公司公告
姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
---|---|---|---|---|---|---|
Jean Pierre Bizzari | 男 | Director | 63 | 6.43万美元 | 未持股 | 2018-06-14 |
Stephen S. Yoder | 男 | Director,Chief Executive Officer and President | 42 | 125.00万美元 | 未持股 | 2018-06-14 |
Michael Richman | 男 | Director | 57 | 7.26万美元 | 未持股 | 2018-06-14 |
Christopher Kiritsy | 男 | Director | 52 | 7.68万美元 | 未持股 | 2018-06-14 |
Ann Barbier | 女 | Director | 54 | 未披露 | 未持股 | 2018-06-14 |
Steven Prelack | 男 | Director | 60 | 7.55万美元 | 未持股 | 2018-06-14 |
James Geraghty | 男 | Director and Chairman | 63 | 26.07万美元 | 未持股 | 2018-06-14 |
高管介绍
注:高管持股数取自最新公司公告
姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
---|---|---|---|---|---|---|
Stephen S. Yoder | 男 | Director,Chief Executive Officer and President | 42 | 125.00万美元 | 未持股 | 2018-06-14 |
Louis A. Matis | 男 | Senior Vice President and Chief Development Officer | 67 | 71.33万美元 | 未持股 | 2018-06-14 |
Allan Reine | 男 | Senior Vice President, Chief Financial Officer and Treasurer | 43 | 196.05万美元 | 未持股 | 2018-06-14 |
董事简历
中英对照 |  中文 |  英文- Jean Pierre Bizzari
-
Jean Pierre Bizzari为Halozyme Therapeutics, Inc.董事会提供了30多年的临床肿瘤学和全球药物批准战略专业知识。他从Celgene公司退休,曾于2012年10月至2015年12月担任执行副总裁兼肿瘤学全球主管,并于2008年至2012年10月担任临床开发肿瘤学高级副总裁,负责监督一系列领先的肿瘤产品的开发和批准,包括RVLIMID来那度胺、Vidaza(阿扎胞苷)、Istodax(罗米地辛)和Abraxane(nab-紫杉醇)。在2008年之前,Bizzari博士担任赛诺菲-安万特临床肿瘤学开发副总裁,负责监督Eloxatin(奥沙利铂)、Taxotere(多西他赛)和Elitek(rasburicase)的批准。之前Bizzari博士是Rhne-Poulenc Rorer临床开发肿瘤学副总裁。Bizzari博士是法国国家癌症研究所科学顾问委员会的成员。Bizzari博士自2005年以来一直是法国国家癌症研究所国际科学委员会的成员,自2010年以来一直是法国国家癌症研究所(INCa)的成员。Bizzari博士还担任生物制药公司Transgene SA以及生物技术公司Compugen Ltd.和Nordic Nanovector ASA的董事会成员。在过去五年中,他还曾在生物制药公司Celator Pharmaceuticals, Inc.、生物技术公司iTeos Therapeutics S.A和Pieris制药公司的董事会任职。他还担任Onxeo S.A.的董事会观察员。Bizzari博士是一名医学博士,毕业于尼斯医学院和肿瘤学专家(在多伦多和蒙特利尔接受培训)。Bizzari博士还是巴黎La Piti é-Salp ê tri è re医院肿瘤科的一名助理。
Jean Pierre Bizzari provides Halozyme Therapeutics, Inc. Board of Directors with over 30 years of clinical oncology and global drug approval strategy expertise. He retired from Celgene Corporation having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012 and oversaw the development and approval of a number of leading oncology products including REVLIMID lenalidomide, VIDAZA (azacitidine), ISTODAX (romidepsin) and ABRAXANE (nab-paclitaxel). Prior to 2008 Dr. Bizzari served as Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin (oxaliplatin), Taxotere (docetaxel) and Elitek (rasburicase). Previously Dr. Bizzari was Vice President, Clinical Development Oncology for Rhne-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005 and the French National Cancer Institute (INCa) since 2010. Dr. Bizzari also serves on the board of directors of Transgene SA, a biopharmaceutical company, and biotechnology companies Compugen Ltd. and Nordic Nanovector ASA. Within the past five years he also served on the board of directors of Celator Pharmaceuticals, Inc., a biopharmaceutical company, and biotechnology companies iTeos Therapeutics S.A, and Pieris Pharmaceuticals, Inc.. He also serves as a board observer at Onxeo S.A. Dr. Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. - Jean Pierre Bizzari为Halozyme Therapeutics, Inc.董事会提供了30多年的临床肿瘤学和全球药物批准战略专业知识。他从Celgene公司退休,曾于2012年10月至2015年12月担任执行副总裁兼肿瘤学全球主管,并于2008年至2012年10月担任临床开发肿瘤学高级副总裁,负责监督一系列领先的肿瘤产品的开发和批准,包括RVLIMID来那度胺、Vidaza(阿扎胞苷)、Istodax(罗米地辛)和Abraxane(nab-紫杉醇)。在2008年之前,Bizzari博士担任赛诺菲-安万特临床肿瘤学开发副总裁,负责监督Eloxatin(奥沙利铂)、Taxotere(多西他赛)和Elitek(rasburicase)的批准。之前Bizzari博士是Rhne-Poulenc Rorer临床开发肿瘤学副总裁。Bizzari博士是法国国家癌症研究所科学顾问委员会的成员。Bizzari博士自2005年以来一直是法国国家癌症研究所国际科学委员会的成员,自2010年以来一直是法国国家癌症研究所(INCa)的成员。Bizzari博士还担任生物制药公司Transgene SA以及生物技术公司Compugen Ltd.和Nordic Nanovector ASA的董事会成员。在过去五年中,他还曾在生物制药公司Celator Pharmaceuticals, Inc.、生物技术公司iTeos Therapeutics S.A和Pieris制药公司的董事会任职。他还担任Onxeo S.A.的董事会观察员。Bizzari博士是一名医学博士,毕业于尼斯医学院和肿瘤学专家(在多伦多和蒙特利尔接受培训)。Bizzari博士还是巴黎La Piti é-Salp ê tri è re医院肿瘤科的一名助理。
- Jean Pierre Bizzari provides Halozyme Therapeutics, Inc. Board of Directors with over 30 years of clinical oncology and global drug approval strategy expertise. He retired from Celgene Corporation having served as Executive Vice President and Global Head of Oncology from October 2012 to December 2015 and as Senior Vice President for Clinical Development Oncology from 2008 to October 2012 and oversaw the development and approval of a number of leading oncology products including REVLIMID lenalidomide, VIDAZA (azacitidine), ISTODAX (romidepsin) and ABRAXANE (nab-paclitaxel). Prior to 2008 Dr. Bizzari served as Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin (oxaliplatin), Taxotere (docetaxel) and Elitek (rasburicase). Previously Dr. Bizzari was Vice President, Clinical Development Oncology for Rhne-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France's National Cancer Institute. Dr. Bizzari has also been a member of the international scientific committee of the French National Cancer Research Institute since 2005 and the French National Cancer Institute (INCa) since 2010. Dr. Bizzari also serves on the board of directors of Transgene SA, a biopharmaceutical company, and biotechnology companies Compugen Ltd. and Nordic Nanovector ASA. Within the past five years he also served on the board of directors of Celator Pharmaceuticals, Inc., a biopharmaceutical company, and biotechnology companies iTeos Therapeutics S.A, and Pieris Pharmaceuticals, Inc.. He also serves as a board observer at Onxeo S.A. Dr. Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris.
- Stephen S. Yoder
-
Stephen S. Yoder.Stephen S. Yoder于2010年1月加入Pieris Operating担任首席执行官。并购交易一生效,他就加入Pieris董事会,并被选为首席执行官和总裁。加入Pieris Operating之前,2003年7月到2010年12月他领导MorphoSys AG(一家生物技术公司,参与抗体的开发和研究)知识产权和法律部门,担任总法律顾问。加入MorphoSys AG之前,从1999年9月到2003年6月他在华盛顿特区多家律师事务所任职,主要从事生命科学知识产权实践。 Yoder持有Grove City College 分子生物学和西班牙语学士学位以及The George Washington University Law School荣誉法律博士学位。身为一名律师,他曾被授权在the United States Patent and Trademark Office实习,以及马里兰地区和华盛顿特区。
Stephen S. Yoder,Stephen S. Yoder joined Pieris Pharmaceuticals GmbH as Chief Executive Officer in January 2010. He joined the Board of Directors of Pieris and was appointed as Chief Executive Officer and President in 2014. Prior to joining Pieris Pharmaceuticals GmbH, from July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. Prior to MorphoSys AG, from September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. As an attorney, he is licensed to practice before the United States Patent and Trademark Office, and in the jurisdictions of Maryland and Washington, D.C. - Stephen S. Yoder.Stephen S. Yoder于2010年1月加入Pieris Operating担任首席执行官。并购交易一生效,他就加入Pieris董事会,并被选为首席执行官和总裁。加入Pieris Operating之前,2003年7月到2010年12月他领导MorphoSys AG(一家生物技术公司,参与抗体的开发和研究)知识产权和法律部门,担任总法律顾问。加入MorphoSys AG之前,从1999年9月到2003年6月他在华盛顿特区多家律师事务所任职,主要从事生命科学知识产权实践。 Yoder持有Grove City College 分子生物学和西班牙语学士学位以及The George Washington University Law School荣誉法律博士学位。身为一名律师,他曾被授权在the United States Patent and Trademark Office实习,以及马里兰地区和华盛顿特区。
- Stephen S. Yoder,Stephen S. Yoder joined Pieris Pharmaceuticals GmbH as Chief Executive Officer in January 2010. He joined the Board of Directors of Pieris and was appointed as Chief Executive Officer and President in 2014. Prior to joining Pieris Pharmaceuticals GmbH, from July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. Prior to MorphoSys AG, from September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. As an attorney, he is licensed to practice before the United States Patent and Trademark Office, and in the jurisdictions of Maryland and Washington, D.C.
- Michael Richman
-
Michael Richman于2015年4月被任命为公司董事。 Richman最先由Douglas J. Swirsky推荐位董事候选人。 Richman现任行业顾问。 Richman于2013年到2015年8月担任Amplimmune(AstraZeneca Group的一个成员)首席执行官。Amplimmune被AstraZeneca收购之前,他曾先后担任Amplimmune(当时是一家私营生物制品公司,专注于癌症和自身免疫性疾病)总裁、总裁和首席执行官的职位。2002年到2007年 Richman担任MacroGenics(一家临床阶段生物制药公司,专注于发现和开发治疗癌症、自身免疫性疾病和传染病的创新型单克隆抗体类疗法)执行副总裁和首席运营官。 Richman在研究、知识产权和业务发展能力方面有着30多年的丰富经验,包括Chiron Corporation(现名为Novartis )以及MedImmune, Inc.。MedImmune, Inc.被AstraZeneca收购之前,他曾担任该公司企业开发高级副总裁。在 MedImmune任职期间, Richman负责所有的业务开发许可、知识产权法律事务、项目管理和战略规划职能部门,他还成功促进了很多次重要的交易。 Richman是 Opexa Therapeutics, Inc. Pieris Pharmaceuticals, Inc.(公共公司)以及 Madison Vaccines, Inc(私营公司)董事。他曾担任Cougar Biotechnology董事,直到该公司于2009年7月与Johnson & Johnson进行并购之后才停止任职。 Richman持有the University of California达维斯分校遗传学和分子生物学理学学士学位;以及San Francisco State University国际业务工商管理学硕士学位。
Michael Richman co-founded our company and has served as our President, Chief Executive Officer and a member of our board of directors since October 2015. Mr. Richman served as President and Chief Executive Officer of Amplimmune, Inc. now MedImmune, LLC, a biopharmaceutical company focused on immuno-oncology, from 2007 to August 2015 including through Amplimmune's acquisition by AstraZeneca plc in October 2013. Before Amplimmune, Mr. Richman served as Executive Vice President and Chief Operating Officer of MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2002 to 2007. Mr. Richman joined MacroGenics with approximately 20 years' experience in corporate business development within the biotechnology industry. Mr. Richman has served as a director of Pieris Pharmaceuticals, Inc., a public company, since December 2014 and as a director of Madison Vaccines, Inc., a private company, since May 2014. Mr. Richman was previously a member of the board of directors of GenVec, Inc. from April 2015 until its acquisition by Intrexon Corporation in June 2017 and Opexa Therapeutics, Inc. from June 2006 until its acquisition by Acer Therapeutics in September 2017. Mr. Richman received a B.S. in genetics and molecular biology from the University of California at Davis and an M.S.B.A. in international business from San Francisco State University. - Michael Richman于2015年4月被任命为公司董事。 Richman最先由Douglas J. Swirsky推荐位董事候选人。 Richman现任行业顾问。 Richman于2013年到2015年8月担任Amplimmune(AstraZeneca Group的一个成员)首席执行官。Amplimmune被AstraZeneca收购之前,他曾先后担任Amplimmune(当时是一家私营生物制品公司,专注于癌症和自身免疫性疾病)总裁、总裁和首席执行官的职位。2002年到2007年 Richman担任MacroGenics(一家临床阶段生物制药公司,专注于发现和开发治疗癌症、自身免疫性疾病和传染病的创新型单克隆抗体类疗法)执行副总裁和首席运营官。 Richman在研究、知识产权和业务发展能力方面有着30多年的丰富经验,包括Chiron Corporation(现名为Novartis )以及MedImmune, Inc.。MedImmune, Inc.被AstraZeneca收购之前,他曾担任该公司企业开发高级副总裁。在 MedImmune任职期间, Richman负责所有的业务开发许可、知识产权法律事务、项目管理和战略规划职能部门,他还成功促进了很多次重要的交易。 Richman是 Opexa Therapeutics, Inc. Pieris Pharmaceuticals, Inc.(公共公司)以及 Madison Vaccines, Inc(私营公司)董事。他曾担任Cougar Biotechnology董事,直到该公司于2009年7月与Johnson & Johnson进行并购之后才停止任职。 Richman持有the University of California达维斯分校遗传学和分子生物学理学学士学位;以及San Francisco State University国际业务工商管理学硕士学位。
- Michael Richman co-founded our company and has served as our President, Chief Executive Officer and a member of our board of directors since October 2015. Mr. Richman served as President and Chief Executive Officer of Amplimmune, Inc. now MedImmune, LLC, a biopharmaceutical company focused on immuno-oncology, from 2007 to August 2015 including through Amplimmune's acquisition by AstraZeneca plc in October 2013. Before Amplimmune, Mr. Richman served as Executive Vice President and Chief Operating Officer of MacroGenics, Inc., a biopharmaceutical company focused on the treatment of cancer, from 2002 to 2007. Mr. Richman joined MacroGenics with approximately 20 years' experience in corporate business development within the biotechnology industry. Mr. Richman has served as a director of Pieris Pharmaceuticals, Inc., a public company, since December 2014 and as a director of Madison Vaccines, Inc., a private company, since May 2014. Mr. Richman was previously a member of the board of directors of GenVec, Inc. from April 2015 until its acquisition by Intrexon Corporation in June 2017 and Opexa Therapeutics, Inc. from June 2006 until its acquisition by Acer Therapeutics in September 2017. Mr. Richman received a B.S. in genetics and molecular biology from the University of California at Davis and an M.S.B.A. in international business from San Francisco State University.
- Christopher Kiritsy
-
Christopher Kiritsy,Christopher Kiritsy于2016年9月加入Pieris董事会。Kiritsy先生是Arisaph Pharmaceuticals,Inc.的联合创始人,自2005年起担任Arisaph&8217;的总裁兼首席执行官。在加入ARISAPH之前,Kiritsy先生曾担任KOS Pharmaceuticals,Inc.的执行Vice President、企业发展和首席财务官,在该公司从初创企业发展成为高利润、公开交易的商业公司的过程中,他发挥了关键的运营作用。在KOS的10年任期内,Kiritsy先生领导了超过10个主要的企业发展交易,并筹集了大约5亿美元的公共股本,包括KOS’;的首次公开募股。KOS于2016年被雅培公司以37亿美元收购。
Christopher Kiritsy,Christopher Kiritsy joined the Board of Directors of Pieris in September 2016. Mr. Kiritsy is a co-founder of Arisaph Pharmaceuticals, Inc. “Arisaph” and served as Arisaph’s President and Chief Executive Officer since 2005. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played a key operating role in building the company from start-up to highly profitable, publicly traded, commercial company. During his 10-year tenure at Kos, Mr. Kiritsy spearheaded more than 10 major corporate development transactions and raised approximately $500 million in public equity, including Kos’s initial public offering. Kos was acquired by Abbott Laboratories for $3.7 billion in 2016. - Christopher Kiritsy,Christopher Kiritsy于2016年9月加入Pieris董事会。Kiritsy先生是Arisaph Pharmaceuticals,Inc.的联合创始人,自2005年起担任Arisaph&8217;的总裁兼首席执行官。在加入ARISAPH之前,Kiritsy先生曾担任KOS Pharmaceuticals,Inc.的执行Vice President、企业发展和首席财务官,在该公司从初创企业发展成为高利润、公开交易的商业公司的过程中,他发挥了关键的运营作用。在KOS的10年任期内,Kiritsy先生领导了超过10个主要的企业发展交易,并筹集了大约5亿美元的公共股本,包括KOS’;的首次公开募股。KOS于2016年被雅培公司以37亿美元收购。
- Christopher Kiritsy,Christopher Kiritsy joined the Board of Directors of Pieris in September 2016. Mr. Kiritsy is a co-founder of Arisaph Pharmaceuticals, Inc. “Arisaph” and served as Arisaph’s President and Chief Executive Officer since 2005. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played a key operating role in building the company from start-up to highly profitable, publicly traded, commercial company. During his 10-year tenure at Kos, Mr. Kiritsy spearheaded more than 10 major corporate development transactions and raised approximately $500 million in public equity, including Kos’s initial public offering. Kos was acquired by Abbott Laboratories for $3.7 billion in 2016.
- Ann Barbier
-
Ann Barbier自2017年11月起担任首席医疗官。2015年6月至2017年10月,Barbier博士曾在生物制药公司Agios Pharmaceuticals Inc.担任罕见遗传病临床开发Vice President,在此期间,她领导了罕见良性血液病小分子的开发计划。从2007年到2015年5月,Barbier博士受聘于制药公司Shire plc,最近担任临床开发高级总监。Barbier博士在比利时金特大学(University of Gent,Belgium)获得药理学硕士学位和博士学位,并在比利时布鲁塞尔自由大学(Free University of Brussels)获得理学硕士学位。她在孟菲斯的田纳西大学(University of Tennessee)追求博士后奖学金。
Ann Barbier has served as chief medical officer since November 2017. Dr. Barbier was previously vice president of clinical development, rare genetic diseases, at Agios Pharmaceuticals Inc., a biopharmaceutical company, from June 2015 to October 2017 during which time she led the development program of a small molecule in rare benign hematological diseases. From 2007 until May 2015 Dr. Barbier was employed by Shire plc, a pharmaceutical company, most recently as senior director of clinical development. Dr. Barbier received an M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis. - Ann Barbier自2017年11月起担任首席医疗官。2015年6月至2017年10月,Barbier博士曾在生物制药公司Agios Pharmaceuticals Inc.担任罕见遗传病临床开发Vice President,在此期间,她领导了罕见良性血液病小分子的开发计划。从2007年到2015年5月,Barbier博士受聘于制药公司Shire plc,最近担任临床开发高级总监。Barbier博士在比利时金特大学(University of Gent,Belgium)获得药理学硕士学位和博士学位,并在比利时布鲁塞尔自由大学(Free University of Brussels)获得理学硕士学位。她在孟菲斯的田纳西大学(University of Tennessee)追求博士后奖学金。
- Ann Barbier has served as chief medical officer since November 2017. Dr. Barbier was previously vice president of clinical development, rare genetic diseases, at Agios Pharmaceuticals Inc., a biopharmaceutical company, from June 2015 to October 2017 during which time she led the development program of a small molecule in rare benign hematological diseases. From 2007 until May 2015 Dr. Barbier was employed by Shire plc, a pharmaceutical company, most recently as senior director of clinical development. Dr. Barbier received an M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis.
- Steven Prelack
-
Steven Prelack,自2003年4月起担任董事是。目前VetCor(拥有并经营全国各地的88家兽医院)的高级副总裁兼首席运营官。自2010年5月起担任此职。自2001年起担任VelQuest Corporation(医药行业的自动化一致性测试软件解决方案供应商)的高级副总裁、财务总监及财务主管。在这方面,他负责监督销售,业务开发,运营和财务。他也是Codeco Corporation(定制电阻和开关的设计商和制造商)的董事。从2007年到2009年担任BioVex的董事及审核委员会主席。他是注册会计师,于1979年从马萨诸塞大学阿默斯特分校获工商管理学士学位,是企业董事协会的成员。
Steven Prelack has served on Aerpio’s board of directors since March 2017. Mr. Prelack has been the Chief Operating Officer and Senior Vice President of VetCor since 2010. He is a director at Galectin Therapeutics and Pieris, Mr. Prelack holds a CPA and has a B.B.A. in Finance and Accounting from the University of Massachusetts, Amherst. - Steven Prelack,自2003年4月起担任董事是。目前VetCor(拥有并经营全国各地的88家兽医院)的高级副总裁兼首席运营官。自2010年5月起担任此职。自2001年起担任VelQuest Corporation(医药行业的自动化一致性测试软件解决方案供应商)的高级副总裁、财务总监及财务主管。在这方面,他负责监督销售,业务开发,运营和财务。他也是Codeco Corporation(定制电阻和开关的设计商和制造商)的董事。从2007年到2009年担任BioVex的董事及审核委员会主席。他是注册会计师,于1979年从马萨诸塞大学阿默斯特分校获工商管理学士学位,是企业董事协会的成员。
- Steven Prelack has served on Aerpio’s board of directors since March 2017. Mr. Prelack has been the Chief Operating Officer and Senior Vice President of VetCor since 2010. He is a director at Galectin Therapeutics and Pieris, Mr. Prelack holds a CPA and has a B.B.A. in Finance and Accounting from the University of Massachusetts, Amherst.
- James Geraghty
-
James Geraghty自2016年7月以来一直担任我们的董事会成员。Geraghty先生是一位行业领导者,拥有超过30年的战略和领导经验,包括在生物技术公司开发和商业化创新疗法的执行团队中担任超过20年的高级成员。2013年5月至2016年12月,Geraghty先生是Third Rock Ventures(领先的生物技术风险投资和公司组建基金)的常驻企业家。从2011年4月到2012年12月,Geraghty先生担任赛诺菲公司(Sanofi)的高级副总裁,这是一家全球性的梦百合公司。在此之前,他曾于1992年至2011年4月在生物技术公司健赞公司(Genzyme)担任多个高级管理职位,包括2007年1月至2011年4月担任高级副总裁,International Development。Geraghty先生目前担任Orchard Therapeutics plc公司、IderaPharmaceuticals,Inc.公司或IDERA公司和Pieris制药公司公司的董事会主席,并担任Voyager公司(一家上市公司)的董事会成员。他此前曾担任瞻博制药公司的董事会主席,以及Bluebird Bio Inc.和GTC BioTherapeutics,Inc.的董事。Geraghty先生在乔治敦大学(Georgetown University)获得英语学士学位,在宾夕法尼亚大学(University of Pennsylvania)获得心理学硕士学位,在耶鲁大学法学院(Yale Law School)获得法学博士学位。
James Geraghty has served on our board of directors since July 2016. Mr. Geraghty is an industry leader with over 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From May 2013 to December 2016 Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund. From April 2011 to December 2012 Mr. Geraghty served as a senior vice president of Sanofi, a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to April 2011 including as senior vice president, international development from January 2007 to April 2011. Mr. Geraghty currently serves as chairman of the board of directors of Orchard Therapeutics plc, Idera Pharmaceuticals, Inc., or Idera, and Pieris Pharmaceuticals, Inc., each publicly traded companies, and as a member of the board of directors of Voyager, a publicly traded company. He previously served as chairman of the board of Juniper Pharmaceuticals, Inc. and as a director of bluebird bio Inc. and GTC Biotherapeutics, Inc. Mr. Geraghty received a B.A. in English from Georgetown University, an M.S. in Psychology from the University of Pennsylvania and a J.D. From Yale Law School. - James Geraghty自2016年7月以来一直担任我们的董事会成员。Geraghty先生是一位行业领导者,拥有超过30年的战略和领导经验,包括在生物技术公司开发和商业化创新疗法的执行团队中担任超过20年的高级成员。2013年5月至2016年12月,Geraghty先生是Third Rock Ventures(领先的生物技术风险投资和公司组建基金)的常驻企业家。从2011年4月到2012年12月,Geraghty先生担任赛诺菲公司(Sanofi)的高级副总裁,这是一家全球性的梦百合公司。在此之前,他曾于1992年至2011年4月在生物技术公司健赞公司(Genzyme)担任多个高级管理职位,包括2007年1月至2011年4月担任高级副总裁,International Development。Geraghty先生目前担任Orchard Therapeutics plc公司、IderaPharmaceuticals,Inc.公司或IDERA公司和Pieris制药公司公司的董事会主席,并担任Voyager公司(一家上市公司)的董事会成员。他此前曾担任瞻博制药公司的董事会主席,以及Bluebird Bio Inc.和GTC BioTherapeutics,Inc.的董事。Geraghty先生在乔治敦大学(Georgetown University)获得英语学士学位,在宾夕法尼亚大学(University of Pennsylvania)获得心理学硕士学位,在耶鲁大学法学院(Yale Law School)获得法学博士学位。
- James Geraghty has served on our board of directors since July 2016. Mr. Geraghty is an industry leader with over 30 years of strategic and leadership experience, including more than 20 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. From May 2013 to December 2016 Mr. Geraghty was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture and company-formation fund. From April 2011 to December 2012 Mr. Geraghty served as a senior vice president of Sanofi, a global healthcare company. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, from 1992 to April 2011 including as senior vice president, international development from January 2007 to April 2011. Mr. Geraghty currently serves as chairman of the board of directors of Orchard Therapeutics plc, Idera Pharmaceuticals, Inc., or Idera, and Pieris Pharmaceuticals, Inc., each publicly traded companies, and as a member of the board of directors of Voyager, a publicly traded company. He previously served as chairman of the board of Juniper Pharmaceuticals, Inc. and as a director of bluebird bio Inc. and GTC Biotherapeutics, Inc. Mr. Geraghty received a B.A. in English from Georgetown University, an M.S. in Psychology from the University of Pennsylvania and a J.D. From Yale Law School.
高管简历
中英对照 |  中文 |  英文- Stephen S. Yoder
Stephen S. Yoder.Stephen S. Yoder于2010年1月加入Pieris Operating担任首席执行官。并购交易一生效,他就加入Pieris董事会,并被选为首席执行官和总裁。加入Pieris Operating之前,2003年7月到2010年12月他领导MorphoSys AG(一家生物技术公司,参与抗体的开发和研究)知识产权和法律部门,担任总法律顾问。加入MorphoSys AG之前,从1999年9月到2003年6月他在华盛顿特区多家律师事务所任职,主要从事生命科学知识产权实践。 Yoder持有Grove City College 分子生物学和西班牙语学士学位以及The George Washington University Law School荣誉法律博士学位。身为一名律师,他曾被授权在the United States Patent and Trademark Office实习,以及马里兰地区和华盛顿特区。
Stephen S. Yoder,Stephen S. Yoder joined Pieris Pharmaceuticals GmbH as Chief Executive Officer in January 2010. He joined the Board of Directors of Pieris and was appointed as Chief Executive Officer and President in 2014. Prior to joining Pieris Pharmaceuticals GmbH, from July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. Prior to MorphoSys AG, from September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. As an attorney, he is licensed to practice before the United States Patent and Trademark Office, and in the jurisdictions of Maryland and Washington, D.C.- Stephen S. Yoder.Stephen S. Yoder于2010年1月加入Pieris Operating担任首席执行官。并购交易一生效,他就加入Pieris董事会,并被选为首席执行官和总裁。加入Pieris Operating之前,2003年7月到2010年12月他领导MorphoSys AG(一家生物技术公司,参与抗体的开发和研究)知识产权和法律部门,担任总法律顾问。加入MorphoSys AG之前,从1999年9月到2003年6月他在华盛顿特区多家律师事务所任职,主要从事生命科学知识产权实践。 Yoder持有Grove City College 分子生物学和西班牙语学士学位以及The George Washington University Law School荣誉法律博士学位。身为一名律师,他曾被授权在the United States Patent and Trademark Office实习,以及马里兰地区和华盛顿特区。
- Stephen S. Yoder,Stephen S. Yoder joined Pieris Pharmaceuticals GmbH as Chief Executive Officer in January 2010. He joined the Board of Directors of Pieris and was appointed as Chief Executive Officer and President in 2014. Prior to joining Pieris Pharmaceuticals GmbH, from July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. Prior to MorphoSys AG, from September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. As an attorney, he is licensed to practice before the United States Patent and Trademark Office, and in the jurisdictions of Maryland and Washington, D.C.
- Louis A. Matis
Louis A. Matis 2015年8月17日被任命为高级副总裁兼首席开发官。加盟Pieris之前,自2011年6月起 Matis 博士出任Alexion Pharmaceuticals公司战略评价的执行董事,在那里1993年至2000年还任职于此。其间提到首席科学官的职务,并曾在发现一流的补体抑制剂单克隆抗体Soliris_依库珠单抗起主导作用。2011年重新加入Alexion公司之前,2000年至2006年Matis 博士曾担任CGI Pharmaceuticals, Inc.的首席执行官;2007年至2010年,担任免疫耐受研究所的首席执行官。1977年至1993年加盟Alexion公司, Matis 博士担任美国国家癌症研究所(NCI)、美国国立卫生研究院和FDA中心生物制品评价和研究的高级研究和临床职务。 Matis 博士获得了 Amherst College的学士学位,University of Pennsylvania Perelman School of Medicine的医学博士;在 University of Chicago Hospitals and Clinics和NCI肿瘤内科进行内科的临床培训。 Matis 博士是重大的科学和医学期刊120多期出版物的作者,是多项专利的共同发明人。
Louis A. Matis, M.D.,Louis A. Matis was appointed Senior Vice President and Chief Development Officer in August 2015. Prior to joining Pieris, Dr. Matis served since June 2011 as Executive Director, Strategic Evaluation at Alexion Pharmaceuticals, where he also served from 1993 to 2000 during which time he advanced to the position of Chief Scientific Officer and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris® eculizumab. Before re-joining Alexion in 2011 Dr. Matis served as Chief Executive Officer of CGI Pharmaceuticals, Inc. from 2000 to 2006 and of the Immune Tolerance Institute from 2007 to 2010. From 1977 until joining Alexion in 1993 Dr. Matis held senior research and clinical positions at the National Cancer Institute (the NCI), National Institutes of Health and the FDA Center for Biologics Evaluation and Research. Dr. Matis received a B.A. from Amherst College, an M.D. from the University of Pennsylvania, Perelman School of Medicine, and his clinical training in Internal Medicine at the University of Chicago Hospitals and Clinics, and in Medical Oncology at the NCI. Dr. Matis is the author of over 120 publications in major scientific and medical journals and is a co-inventor on multiple patents.- Louis A. Matis 2015年8月17日被任命为高级副总裁兼首席开发官。加盟Pieris之前,自2011年6月起 Matis 博士出任Alexion Pharmaceuticals公司战略评价的执行董事,在那里1993年至2000年还任职于此。其间提到首席科学官的职务,并曾在发现一流的补体抑制剂单克隆抗体Soliris_依库珠单抗起主导作用。2011年重新加入Alexion公司之前,2000年至2006年Matis 博士曾担任CGI Pharmaceuticals, Inc.的首席执行官;2007年至2010年,担任免疫耐受研究所的首席执行官。1977年至1993年加盟Alexion公司, Matis 博士担任美国国家癌症研究所(NCI)、美国国立卫生研究院和FDA中心生物制品评价和研究的高级研究和临床职务。 Matis 博士获得了 Amherst College的学士学位,University of Pennsylvania Perelman School of Medicine的医学博士;在 University of Chicago Hospitals and Clinics和NCI肿瘤内科进行内科的临床培训。 Matis 博士是重大的科学和医学期刊120多期出版物的作者,是多项专利的共同发明人。
- Louis A. Matis, M.D.,Louis A. Matis was appointed Senior Vice President and Chief Development Officer in August 2015. Prior to joining Pieris, Dr. Matis served since June 2011 as Executive Director, Strategic Evaluation at Alexion Pharmaceuticals, where he also served from 1993 to 2000 during which time he advanced to the position of Chief Scientific Officer and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris® eculizumab. Before re-joining Alexion in 2011 Dr. Matis served as Chief Executive Officer of CGI Pharmaceuticals, Inc. from 2000 to 2006 and of the Immune Tolerance Institute from 2007 to 2010. From 1977 until joining Alexion in 1993 Dr. Matis held senior research and clinical positions at the National Cancer Institute (the NCI), National Institutes of Health and the FDA Center for Biologics Evaluation and Research. Dr. Matis received a B.A. from Amherst College, an M.D. from the University of Pennsylvania, Perelman School of Medicine, and his clinical training in Internal Medicine at the University of Chicago Hospitals and Clinics, and in Medical Oncology at the NCI. Dr. Matis is the author of over 120 publications in major scientific and medical journals and is a co-inventor on multiple patents.
- Allan Reine
Allan Reine自2019年9月起担任我们的首席财务官。在加入Foghorn之前,Reine博士于2017年8月至2019年9月担任Pieris Pharmaceuticals的首席财务官。从2012年8月到2017年8月,Reine博士是Lombard Odier Asset Management的投资组合经理,他在该公司经营着专注于生物技术和制药公司的梦百合投资组合。加入Lombard Odier之前,Reine从2003年到2012年8月担任多个基金的梦百合投资组合经理,包括Citi Principal Strategies、SAC Capital、Trivium Capital和Alexandra Investment Management。他的职业生涯始于2001年任职CIBC World Markets,在那里他曾从事生物技术投资银行和生物技术股票研究。Reine博士在多伦多大学(University of Toronto)获得医学博士学位,在西安大略大学(University of Western Ontario)获得统计学学士学位。
Allan Reine has served as our Chief Financial Officer since September 2019. Prior to joining Foghorn, Dr. Reine served as Chief Financial Officer of Pieris Pharmaceuticals from August 2017 to September 2019. From August 2012 through August 2017 Dr. Reine was a portfolio manager at Lombard Odier Asset Management, where he ran a healthcare portfolio focused on biotechnology and pharmaceutical companies. Before joining Lombard Odier, from 2003 through August 2012 Dr. Reine served as a healthcare portfolio manager at various funds, including Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. Dr. Reine began his career in 2001 at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine received his M.D. from the University of Toronto and his B.S. in Statistical Sciences from the University of Western Ontario.- Allan Reine自2019年9月起担任我们的首席财务官。在加入Foghorn之前,Reine博士于2017年8月至2019年9月担任Pieris Pharmaceuticals的首席财务官。从2012年8月到2017年8月,Reine博士是Lombard Odier Asset Management的投资组合经理,他在该公司经营着专注于生物技术和制药公司的梦百合投资组合。加入Lombard Odier之前,Reine从2003年到2012年8月担任多个基金的梦百合投资组合经理,包括Citi Principal Strategies、SAC Capital、Trivium Capital和Alexandra Investment Management。他的职业生涯始于2001年任职CIBC World Markets,在那里他曾从事生物技术投资银行和生物技术股票研究。Reine博士在多伦多大学(University of Toronto)获得医学博士学位,在西安大略大学(University of Western Ontario)获得统计学学士学位。
- Allan Reine has served as our Chief Financial Officer since September 2019. Prior to joining Foghorn, Dr. Reine served as Chief Financial Officer of Pieris Pharmaceuticals from August 2017 to September 2019. From August 2012 through August 2017 Dr. Reine was a portfolio manager at Lombard Odier Asset Management, where he ran a healthcare portfolio focused on biotechnology and pharmaceutical companies. Before joining Lombard Odier, from 2003 through August 2012 Dr. Reine served as a healthcare portfolio manager at various funds, including Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. Dr. Reine began his career in 2001 at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine received his M.D. from the University of Toronto and his B.S. in Statistical Sciences from the University of Western Ontario.